Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | FABP3 | P05413 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24796000 | 0.84 | L3MBTL1 (0.41) | TSHRL3MBTL1PDE7ALMNAALDH1A1 | |
| SCHEMBL21389103 | 0.82 | KMT2A (0.44) | GAAFABP3FABP4L3MBTL1LMNA | |
| SCHEMBL21389356 | 0.82 | HPGD (0.43) | TSHRGAAL3MBTL1PDE7ALMNA | |
| SCHEMBL21383907 | 0.80 | TSHR (0.35) | TSHRGAAFABP3FABP4L3MBTL1 | |
| SCHEMBL21389091 | 0.80 | KMT2A (0.40) | TSHRGAAFABP3FABP4L3MBTL1 | |
| SCHEMBL24796263 | 0.77 | USP2 (0.39) | GAAFABP3FABP4L3MBTL1LMNA | |
| SCHEMBL24796268 | 0.77 | ALDH1A1 (0.40) | GAAFABP3FABP4L3MBTL1PDE7A | |
| SCHEMBL21383876 | 0.77 | ALDH1A1 (0.39) | GAAFABP3FABP4L3MBTL1ALDH1A1 | |
| SCHEMBL21389194 | 0.77 | GAA (0.36) | GAAFABP3FABP4L3MBTL1LMNA | |
| SCHEMBL21389211 | 0.77 | GAA (0.55) | TSHRGAAL3MBTL1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11535660-B1 | Modulators of G-protein coupled receptors | Cannot Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | TSHR 140/4885GAA 1526/4885FABP3 666/4885 |
| US-11535660-B1 | Modulators of G-protein coupled receptors | GIPR, GLP1R, GCGR | TSHR 142/4885GAA 1536/4885FABP3 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.